37 83

Cited 0 times in

Long-term Outcomes of Protocol-Based Treatment for Newly Diagnosed Medulloblastoma

DC Field Value Language
dc.contributor.author김동석-
dc.contributor.author김세훈-
dc.contributor.author박은경-
dc.contributor.author심규원-
dc.contributor.author안원기-
dc.contributor.author유철주-
dc.contributor.author윤홍인-
dc.contributor.author한승민-
dc.contributor.author한정우-
dc.date.accessioned2024-05-23T03:21:50Z-
dc.date.available2024-05-23T03:21:50Z-
dc.date.issued2024-04-
dc.identifier.issn1598-2998-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/199212-
dc.description.abstractPurpose The Korean Society of Pediatric Neuro-Oncology (KSPNO) conducted treatment strategies for children with medulloblastoma (MB) by using alkylating agents for maintenance chemotherapy or tandem high-dose chemotherapy (HDC) with autologous stem cell rescue (ASCR) according to the risk stratification. The purpose of the study was to assess treatment outcomes and complications based on risk-adapted treatment and HDC.Materials and Methods Fifty-nine patients diagnosed with MB were enrolled in this study. Patients in the standard-risk (SR) group received radiotherapy (RT) after surgery and chemotherapy using the KSPNO M051 regimen. Patients in the high-risk (HR) group received two and four chemotherapy cycles according to the KSPNO S081 protocol before and after reduced RT for age following surgery and two cycles of tandem HDC with ASCR consolidation treatment.Results In the SR group, 24 patients showed 5-year event-free survival (EFS) and overall survival (OS) estimates of 86.7% (95% confidence interval [CI], 73.6 to 100) and 95.8% (95% CI, 88.2 to 100), respectively. In the HR group, more infectious complications and mortality occurred during the second HDC than during the first. In the HR group, the 5-year EFS and OS estimates were 65.5% (95% CI, 51.4 to 83.4) and 72.3% (95% CI, 58.4 to 89.6), respectively.Conclusion High intensity of alkylating agents for SR resulted in similar outcomes but with a high incidence of hematologic toxicity. Tandem HDC with ASCR for HR induced favorable EFS and OS estimates compared to those reported previously. However, infectious complications and treatment-related mortalities suggest that a reduced chemotherapy dose is necessary, especially for the second HDC.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish, Korean-
dc.publisherOfficial journal of Korean Cancer Association-
dc.relation.isPartOfCANCER RESEARCH AND TREATMENT-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAlkylating Agents / therapeutic use-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols / adverse effects-
dc.subject.MESHCerebellar Neoplasms* / diagnosis-
dc.subject.MESHCerebellar Neoplasms* / drug therapy-
dc.subject.MESHChild-
dc.subject.MESHCombined Modality Therapy-
dc.subject.MESHHematopoietic Stem Cell Transplantation*-
dc.subject.MESHHumans-
dc.subject.MESHMedulloblastoma* / drug therapy-
dc.subject.MESHMedulloblastoma* / therapy-
dc.titleLong-term Outcomes of Protocol-Based Treatment for Newly Diagnosed Medulloblastoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Neurosurgery (신경외과학교실)-
dc.contributor.googleauthorWon Kee Ahn-
dc.contributor.googleauthorSeung Min Hahn-
dc.contributor.googleauthorHong In Yoon-
dc.contributor.googleauthorJeongshim Lee-
dc.contributor.googleauthorEun Kyung Park-
dc.contributor.googleauthorKyu Won Shim-
dc.contributor.googleauthorDong Seok Kim-
dc.contributor.googleauthorChang-Ok Suh-
dc.contributor.googleauthorSe Hoon Kim-
dc.contributor.googleauthorChuhl Joo Lyu-
dc.contributor.googleauthorJung Woo Han-
dc.identifier.doi10.4143/crt.2023.865-
dc.contributor.localIdA00402-
dc.contributor.localIdA00610-
dc.contributor.localIdA01607-
dc.contributor.localIdA01919-
dc.contributor.localIdA02187-
dc.contributor.localIdA05357-
dc.contributor.localIdA02524-
dc.contributor.localIdA04777-
dc.contributor.localIdA04299-
dc.contributor.localIdA04325-
dc.relation.journalcodeJ00453-
dc.identifier.eissn2005-9256-
dc.identifier.pmid38037318-
dc.subject.keywordAutologous stem cell rescue-
dc.subject.keywordChildren-
dc.subject.keywordHigh-dose chemotherapy-
dc.subject.keywordMedulloblastoma-
dc.contributor.alternativeNameKim, Dong Seok-
dc.contributor.affiliatedAuthor김동석-
dc.contributor.affiliatedAuthor김세훈-
dc.contributor.affiliatedAuthor박은경-
dc.contributor.affiliatedAuthor심규원-
dc.contributor.affiliatedAuthor안원기-
dc.contributor.affiliatedAuthor유철주-
dc.contributor.affiliatedAuthor윤홍인-
dc.contributor.affiliatedAuthor한승민-
dc.contributor.affiliatedAuthor한정우-
dc.citation.volume56-
dc.citation.number2-
dc.citation.startPage652-
dc.citation.endPage664-
dc.identifier.bibliographicCitationCANCER RESEARCH AND TREATMENT, Vol.56(2) : 652-664, 2024-04-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.